Aletta's FDA Authorization Sets the Bar Other Robotic Blood-Draw Devices Must Clear
- Aug 24
- 2 min read
Updated: Aug 26
A failed venipuncture is never just an inconvenience.
It means a second stick, a delayed result, or a hemolyzed sample sent back to the lab.
On August 19, 2026, the FDA authorized Aletta, the first standalone robotic device cleared to draw blood from a patient's arm without hands-on operator involvement.
What the De Novo Pathway Actually Authorizes
Vitestro's authorization came through the De Novo pathway, reserved for low-to-moderate-risk devices with no existing predicate.
Alongside the clearance, the FDA established special controls covering labeling, performance testing, and clinical testing.
Any future robotic phlebotomy device seeking US market entry will need to clear the same bar Aletta just set.
Aletta is authorized for adult outpatients only, and it must operate under the oversight of a phlebotomy-trained supervisor.
The Peer-Reviewed Numbers Behind the Authorization
The authorization draws on the ADOPT trial, published in Clinical Chemistry in April 2026.
Across 1,633 patients at three Dutch outpatient phlebotomy departments, the device achieved a 94.5% first-stick success rate among patients where a suitable vein was identified.
That figure held up in harder cases: 92.7% in patients with difficult venous access, 97.4% in patients with obesity, and 93.4% in patients 65 and older.
Adverse events occurred in 0.6% of procedures, all mild, with no serious events reported.
Ninety percent of patients rated the pain as comparable to or better than manual phlebotomy.
The trial evaluated an investigational version of the device, a detail Vitestro discloses in its own published materials.
One Supervisor, Three Devices
US clinical laboratories report phlebotomist turnover as high as 46% a year, and only 38% of the workforce is credentialed.
Aletta's authorized staffing model lets one supervisor oversee up to three devices running at once.
That ratio, more than the robotics itself, is the detail hospital administrators will study first.
Robots have already taken over the tube, the centrifuge, and the analyzer.
The needle was the last manual step standing.
It just stopped being one.
